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International travel continues to increase in numbers and complexity. Despite the availability of pretravel
health advice, travelers remain at risk for exposure to common organisms as well as emerging pathogens.
With low rates of travel clinic utilization, it is important for the general practitioner to remain aware of
the importance of travel health, risk factors unique to individual patients, and evolving threats. This review
highlights important considerations when evaluating ill travelers, incorporating emerging infectious threats.
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International travel continues to
explode, with over  billion international tourist
arrivals per year1,2 and an estimated  billion by
.3,4 As a risk factor for infectious diseases,
international travel has become an increasingly
complex issue. Reasons for travel are numerous,
and the spectrum of destinations has expanded
with increasing travel to developing countries,
namely, in Asia and Africa.1,2,4,5 While most international travel is for leisure, other reasons include business, education and research, volunteer
work, visiting friends and relatives (VFR), medical tourism, adoption, as well as immigration
and military activities, all of which have their
own unique risks.4 -8 Additionally, travelers themselves are increasingly diverse. Travelers of all
ages, immunocompromised travelers, and travelers with comorbid conditions frequent high-risk destinations.6,9 -12
The percentage of travelers who become ill ranges significantly in published studies (%–%), although a recently published review concluded that
% to % of travelers who visited developing
countries became ill.4 These numbers are affected by patient expectations from travel (whether
they choose to present to care because of travel-associated illness) and regional patterns of disease (those who reside in metropolises close to
a threat may experience it already). Despite high
rates of morbidity associated with travel to developing countries, most travelers do not seek
pretravel counseling. The exact proportion varies
considerably by study, but most reports showed
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rates below %, and in one small study, only
% of Hong Kong travelers received pretravel advice.1,5,7,13-16 However, even in the context of pretravel counseling and receipt of appropriate preventive measures, the rates of morbidity remain
high with up to % of patients reporting illness
during travel in one prospective cohort.1
The most common categories of illnesses reported in travelers are gastrointestinal syndromes, febrile illnesses, dermatologic disorders, and respiratory illnesses.4,5,15,17 The spectrum of potential
pathogens causing these syndromes is incredibly
broad, and emerging threats should be considered.
The impact of international travel on the visited
population and the population to which the traveler returns should also be considered. International travel may contribute to the spread of disease
and disease emergence, in some settings.18 Travelers have been explicitly implicated in the spread of
severe acute respiratory syndrome, influenza HN
virus, measles, mumps, dengue, malaria, and cholera, to name a few.5,19,20
In the setting of increasing international travel, traveler complexity, expanding destinations,
low rates of pretravel counseling, and broad infectious differentials, primary care providers must
become more aware of risk factors for acquisition
of infection and emerging threats when evaluating international travelers. In this review, we
highlight important considerations when evaluating travelers, with a special focus on the risk of
emerging infectious diseases, by placing clinical
syndromes in a travel context.

In epidemiologic studies, time
spent with an exposure dominates risk profiles.
Whether counseling a would-be traveler or evaluating one who has returned with a concern, early in the interview an exposure assessment is required. What did the person actually do when
on travel? Where was this done in terms of
the setting and season, not just location? How
did the person prepare for potential risks? Why
a person chooses to travel, what they intended
to do, what they might have done because opportunities arose? These issues are all vital to
assessing risk. One particular example of this is
VFR travelers. Research has consistently demonstrated a higher risk of acquiring infection in this
group, which in many cases is preventable.21 In
the United States, higher rates of hospitalization
were noted among VFR travelers presenting to
GeoSentinel clinics.22 These travelers have lower
rates of pretravel health visits and longer stays,
which likely contributes to these differences.22,23
A traveler’s specific reason for travel and travel itinerary can unveil unique risk factors as well.
Medical care, adoption, freshwater activities, visiting or caring for the ill, medical tourism, sex
tourism, refugee and other aid work, missionary
work, activities at altitude, diving, food sources,
and accommodations all contribute to a milieu
in which travel-related disease may be acquired
or nontravel-related disease may be exacerbated.
In a study on travelers consulting a travel medicine clinic, % of over  respondents reported at least  risk behavior, and younger travelers
in general participated in more risky behaviors.24
Geographic locations have their own individual risks. GeoSentinel surveillance has documented variable risks for certain infectious syndromes
by geographic region. For instance, malaria was
the most common cause of systemic febrile illness
after travel to sub-Saharan Africa, while dengue
was more frequent for all other locations except
sub-Saharan Africa and Central America.8 Furthermore, certain risks may be confined to specific areas or subregions even if they are commonly considered to be more broadly present. For example, yellow fever is endemic to specific tropical
areas of Africa and Central and South America.
Detailed information about these regions is available to providers through the United States Centers for Disease Control and Prevention (CDC),
European Centre for Disease Prevention and Control (ECDC), World Health Organization (WHO),
and other national-level public health agencies.
Similarly, malaria is present in specific geographic locations, with absence of transmission
at higher altitudes where the vector, the Anopheles mosquito, is not encountered. Seasonal variation is also an important consideration. GeoSentinel surveillance revealed significant seasonal variation in dengue transmission, with more
cases reported from September to December
in South Central Asia with a peak in October.
Rates in the Caribbean were highest between August and December, while March was the peak
Risk of exposure
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month of transmission in South America, reflecting the rainy seasons in these locations.25 Dry
weather also carries specific infectious risks. In
sub-Saharan Africa, the incidence of meningococcal meningitis increases every dry season.26
Additionally, providers should be aware of
known outbreaks (whether it is violence or infectious diseases) and other hazards near the spots
included in a patient’s itinerary. Notifications of
outbreaks can be found on the CDC, ECDC, or
WHO websites. Outbreaks and unrest often are
delineated on the websites of ministries of foreign affairs. In , notable outbreaks include
Ebola virus disease in the Democratic Republic of
the Congo (DRC), with related risk in neighboring countries; Middle East respiratory syndrome
coronavirus (MERS -CoV) in Oman and Saudi
Arabia; a worldwide measles outbreak; and cholera in several locations. Realized risk for emerging infectious diseases in the broad population
of short-term travelers has been low. Although
early cases in Europe of MERS -CoV were associated with Umrah, several large-scale studies examining Hajj and Umrah have failed to identify
cases.21,27,28 Nonetheless, when it is realized, it is
very impactful. South Korea experienced a consequential nosocomial MERS -CoV outbreak associated with a single short-term traveler, and to
a lesser extent so did the United States from Ebola Zaire virus.29 -31
Travel is a common precipitating theme in Disease Outbreak News reports for micro-outbreaks.32
In many of these instances, the traveler was exposed to an established, recognized outbreak.
The purpose of their travel brought them in close
proximity to areas of risk, and so a broad application of usual traveler preparation coupled with
risk communication regarding emerging disease
events, and careful agreement about steps to take
on return if ill, would be beneficial in risk management in similar cases. Respiratory disease from
novel or emerging influenzas and coronaviruses
such as severe acute respiratory syndrome coronavirus are notable exceptions to this. All travelers should understand that the unexpected occurs
and that travel becomes part of their history of
present illness or past medical history, as appropriate. In counseling a traveler, reassurance that
travel can be safe with proper precautions should
not attenuate vigilance with illness on return by
both the provider and patient.
Important patient characteristics to consider include age, pre-existing
medical conditions or comorbidities, and reasons
for travel. Among travelers enrolled in the Global
TravEpiNet, the age range was broad ( month to
 years) with a median age of  years.6 While
increasing age is generally associated with more
underlying medical conditions, and subsequently increased risk of becoming ill when traveling,
one study found that older travelers complied
more with medical advice, took fewer risks, and
had lower rates of illness compared with younger
Patient vulnerabilities
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travelers (% vs %).33 According to Global
TravEpiNet data, over half of all travelers in a single analysis reported  or more medical conditions
and taking at least  daily medication.6 Similarly,
a large cross-sectional study in the greater Boston area found % of travelers had medical comorbidities, % were considered high risk, and
% were immunocompromised.12
Identification of persons with pre-existing
medical conditions and immune compromising
conditions is important, as research suggests
higher incidence of a travel-related illness in individuals with pre-existing medical conditions
and higher rates of hospitalization in immunocompromised individuals when an illness occurs
during travel.34 -36 The number of living immunocompromised persons is expected to increase, especially as indications for biologic agents expand,
such as monoclonal antibodies used to treat rheumatologic and oncologic conditions. A study evaluating  immunocompromised international
travelers seen at Global TravEpiNet sites found
that biologic agents such as tumor necrosis factor
inhibitors were the most commonly used immunosuppressive medications.36 Not only are these
individuals at increased risk of complications related to infection, but pretravel live vaccinations
may be contraindicated (ie, yellow fever or measles, mumps, rubella). Also, the extent to which
a traveler’s activities and stress may contribute
to becoming ill when traveling is underappreciated. Pre-combat stress has well-documented impact on disease and non–battle injury rates among
deployed service members.37 An increased rate of
upper respiratory tract infections with commensurate functional immunodeficiency has been observed in athletes.38
While travelers often do not seek pretravel
health advice, when they do, sources often include general practitioners, family and friends,
and the internet, with low utilization of travel
clinics.17,39,40 However, even in the setting of appropriate counseling and preventive measures,
the rates of morbidity remain high.1 Studies have
demonstrated low rates of insect repellent utilization, vaccine series completion, and proper
utilization of malaria prophylaxis among travelers.13,41- 43 To what extent VFR travelers tighten
their selection of water sources and use of handwashing in cholera zones, or defer ritualistic funeral practices in regions with Ebola virus, for instance, is unknown. Nonetheless, tailored advice
relevant to emerging infectious diseases events
should be incorporated along with usual guidance on maintaining wellness while traveling,
when relevant to the itinerary. For some travelers, their very activity may uniquely precipitate
increased exposure to an emerging infectious disease, as occurred with leptospirosis among adventure athletes from around the world in one
notable event.44
Recommended preventive measures are part of
an important layered approach in travel risk management. In isolation, they have variable efficacy.
614
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This information is important for risk communication of the significance of layered preventative
measures such as those against mosquito- and
food-borne illnesses, for addressing preventative
misconceptions of patients and providers relevant to risk behavior (such as the false idea that
any single prevention step done alone is enough),
and for properly characterizing illness in returned
travelers. For instance, the protective efficacy of
available typhoid vaccination is low and ranges
from % to %.45 On the other hand, the protective efficacy of hepatitis A, B, rabies, MMR,
and varicella vaccinations is high, though none
of them is perfectly protective in every individual.46 While often effective, the actual efficacy of
medication prophylaxis against malaria can vary
widely by circumstance, and the utility of doxycycline for preventing leptospirosis remains unclear.47 Despite this, most infections associated
with travel are preventable, particularly those associated with travel to Africa.2,48
Fever in a traveler: a clinical syndrome in context

Physicians who evaluate ill returned travelers also
must place events in the context of recent travel.
The first steps towards this are defining the clinical syndrome and assessing the incubation period
for risks specific to both cosmopolitan and geographical areas. As physicians, the presenting clinical syndrome is the gateway to our understanding of the patient’s experience with an illness.
What accompanies the patient’s fever—cough,
diarrhea, rash, lymphadenopathy, hepatosplenomegaly, mental status change? Where has the patient been and when—sometimes over months
to years but generally in terms of the last couple
of weeks, several weeks, and longer?49,50 Some of
these relationships are presented in TABLE 1 . How
do they come together with the patient’s travel
behaviors and other factors to suggest how prioritizing the most dangerous and most likely diagnoses impacts management?
A common pitfall in how this thinking is applied is to forget common infectious and noninfectious illnesses that may occur anywhere. Anyone can experience influenza. Travelers may experience intravascular thrombi, vaccine reactions
and other hypersensitivity reactions, consequences of disruptions in chronic disease management,
cancer (particularly breast, testicular, and hematologic in younger travelers), rheumatic diseases,
such as systemic lupus erythematosus, and everything else that happens to people regardless of
whether they are risk takers or because they are
risk takers. Work–travel routine may disrupt usual healthcare use and increase the risk for hard-to-manage conditions while on travel, such as
human papilloma virus and shingles vaccination,
routine oncologic and cardiovascular screening,
and dental maintenance.
Investigating returned travelers with a fever
may pose a challenge to usual clinical laboratory
processes. Assessing samples for parasitic diseases may require specialized techniques with which

TABLE 1

Diagnoses of infectious causes of fever in travelers: clinical syndrome and incubation period matrix (continued on the next page)

Incubation period

Less than 2 weeks

2 to 6 weeks

More than 6 weeks

Travel-associated undifferentiated
fever

Angiostrongyliasis
Arboviral encephalitis
Campylobacteriosis
Coccidioidomycosis, acute
Dengue
Genital ulcer disease
Histoplasmosis, acute
HIV, acute
Influenza
Legionellosis
Leptospirosis
Louse-borne typhus
Malaria
Meningococcemia
Poliomyelitis
Q fever
Rabies
Salmonellosis
Scrub typhus
Shigellosis
Spotted fever
Syphilis
Trypanosomiasis, East African
Typhoid fever
Viral hemorrhagic fever

Acute HIV
Acute schistosomiasis
Amebic liver abscess
Brucellosis
Hepatitis A or E
Leptospirosis
Malaria
Melioidosis
Q fever
Syphilis
Trypanosomiasis, East African
Typhoid fever
Viral hemorrhagic fever

Amebic liver abscess
Chronic mycosis
Hepatitis B
Hepatitis E
Hookworm
Leishmaniasis, visceral
Lymphatic filariasis
Malaria
Melioidosis
Paracapillariasis
Rabies
Schistosomiasis
Strongyloidiasis
Trypanosomiasis, African
Tuberculosis

Fever + mental status changea

Angiostrongyliasis
Arboviral encephalitis
Louse-borne typhus
Malaria
Meningococcemia
Rabies
Scrub typhus
Syphilis
Tick borne encephalitis
Trypanosomiasis, East African
Typhoid fever
Viral encephalitides

Louse-borne typhus
Malaria
Scrub typhus
Syphilis
Trypanosomiasis, East African
Tick borne encephalitis
Typhoid fever
Viral encephalitides

Amebic liver abscess
Chronic mycosis
Malaria
Rabies
Syphilis
Trypanosomiasis, African
Tuberculosis

Fever + hepatomegaly without
splenomegaly

Trypanosomiasis, East African
Viral hepatitides

Schistosomiasis, acute
Trypanosomiasis, East African
Viral hepatitides

Leishmaniasis, visceral
Trypanosomiasis, African
Viral hepatitides

Fever + splenomegaly

Dengue
HIV
Infectious mononucleosis
Leptospirosis
Malaria
Typhoid fever
Typhus
Viral hemorrhagic fever

Brucellosis
Dengue
HIV
Infectious mononucleosis
Leptospirosis
Malaria
Q fever
Schistosomiasis, acute
Typhoid fever
Viral hemorrhagic fever

Leishmaniasis, visceral
Malaria
Tuberculosis

REVIEW ARTICLE

Risk mitigation for travelers

615

TABLE 1

Diagnoses of infectious causes of fever in travelers: clinical syndrome and incubation period matrix (continued from the previous page)

Incubation period

Less than 2 weeks

2 to 6 weeks

More than 6 weeks

Fever + lymphadenopathy

Generalized
Dengue
Disseminated fungal infectionb
HIV, acute
Infectious mononucleosis

Generalized
Dengue
Disseminated fungal infectionb
HIV
Infectious mononucleosis

Generalized
Disseminated fungal infectionb
HIV
Leishmaniasis, visceral

Regional
Anthrax
Bacterial lymphadenitis
Plague
Scrub typhus
Trypanosomiasis
Tularemia

Regional
Nontuberculous mycobacteria
infection
Trypanosomiasis
Tuberculosis

Regional
Blastomycosis
Nontuberculous mycobacteria
infection
Tuberculosis

Local
African tick bite fever
Bacterial lymphadenitis
Sexually transmitted infections

Local
Nontuberculous mycobacteria
infection
Tuberculosis

Local
Nontuberculous mycobacteria
infection
Tuberculosis

Aggressive volume repletion in
setting of
Dengue
Bacterial pneumonia
Disseminated fungal infectionb
Legionellosis
Leptospirosis
Malaria
Q fever
Severe acute respiratory disease
pathogensc
Transfusion lung injury

Bacterial pneumonia
Disseminated fungal infectionb
Katayama fever
Leptospirosis
Loffler’s syndrome
Malaria
Melioidosis
Q fever
Tropical pulmonary eosinophilia

Amebic abscess
Disseminated fungal infectionb
Malaria
Melioidosis
Tuberculosis

Fever + cough or shortness of
breath

This is not an exhaustive list but rather a frame of reference for initial assessment.3,49,50 An individual patient might present with almost any sepsis
clinical syndrome regardless of pathogen, and host factors may attenuate or exacerbate what normally would be a more characteristic syndrome.
Patients may have more than 1 problem, for example, bacterial coinfection following a viral syndrome and occurring seemingly late. A fever and rash
or arthralgia are not included, though borrelia, rickettsioses, meningococcemia, syphilis, typhoid, and viral hemorrhagic fever (VHF) are commonly
associated with the former, and flaviviruses (eg, Dengue and Zika), alphaviruses (eg, Chikungunya), and borrelioses with either or both a rash and
arthralgia. Malaria and VHF should be included in the broader differential diagnosis of fever and diarrhea.
a

In older patients, sepsis may present as decompensated cerebrovascular disease. Fulminant sepsis may show delirium and encephalopathy.

b

In particular, endemic dimorphic yeast such as histoplasmosis, coccidioidomycosis, paracoccidioidomycosis, blastomycosis, and others

c

Such as novel influenza, coronaviruses, New World hantaviruses

even a referral academic medical center may not
be acquainted.51 The local regulatory status of
tropical disease assays, such as those for leptospirosis or dengue fever, or of emerging diseases, may vary. It is useful for physicians to discuss
these issues with their laboratorian counterparts
in advance. While awaiting a definitive diagnosis,
clinicians sometimes try to rely on the presence or
absence of arcane fever patterns, such as tertiary
and quaternary fever patterns that require parasite synchronization in different types of malaria; pulse-temperature disassociation in typhoid
fever and other illness of the reticuloendothelial
system; or saddle-back patterns in dengue fever.
While these may be informative, their individual predictive power is low.
A case Patient Zed (PZ) is a -year-old woman who presents to a clinic with a -day history
of diarrhea and vomiting. You had seen her in
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clinic  weeks prior in preparation for her trip
to eastern Rwanda, her first travel to Africa. She
returned home to a suburb in the United States
last night. PZ has abdominal cramping and feels
lightheaded when standing. She has had  loose
stools in the last  hours, which she says were
watery and large, each time beginning explosively. There was no blood or pus in her stool. Yesterday, she had  vomiting episodes, water and
food remnants without blood. She has hypothyroidism. Her only medications are levothyroxine
and atovaquone/proguanil begun  days prior to
the start of her trip. She has no other past medical or surgical history.
Patient Zed arrived in Rwanda  days before
presentation along with her husband and a group
of friends who sponsored an eastern Rwanda village as part of a twin or sister city relationship.
While they paid visits to homes, churches, and
restaurants, the group stayed in a guest house

accustomed to foreign travelers. They spent  day
in a local game park. She is not aware of having
had sick contacts and says that she was mindful of
safer eating and drinking practices, vector mitigation with permethrin-treated clothes and wearing
mosquito repellent, has adhered to her antimalarial medication prescription, and felt well until
the onset of her symptom’s yesterday. She thinks
that she might have eaten a dodgy snack at the
airport prior to boarding her flight home  days
ago. She had no exposure to fresh water. Review
of the patient’s triage card shows an oral temperature of .ºC, a heart rate of  bpm, and normal blood pressure, respiratory rate, and pulse oximetry. You had observed her enter the room and
she had a normal, rapid gait. In the chair opposite you she conversed comfortably. She appears
to be of European descent.
As you are ready to perform a physical examination while suspecting a traveler’s diarrhea from
an enterotoxigenic Escherichia coli or a similar pervasive threat, you recall that cases of Ebola virus have been recently reported in Goma (DRC),
which abuts the Rwandan border.52,53 You remember your conversation with PZ prior to her trip
and discussing that Rwanda was considered a high
priority for preparedness activities, though it
had not experienced an observed case. You check
the CDC travel notices portal and see no warnings listed for Rwanda.54 Knowing that situations like that in the DRC change quickly, you also
check the WHO Disease Outbreak News and see
an update on the DRC from  days ago that said
there were no confirmed cases outside the DRC.32
You start rising from your desk as a Twitter feed
alert appears on the task bar of your screen, and
it is from the WHO Director General confirming
that cases have been found in South Kivu near
the Rwandan border. This raises the risk for Rwanda of experiencing the current emergency, but it
has not been observed yet. Taking a closer look
at an online map, the place where your traveler
visited is well away from the DRC border. Nonetheless, you ask the patient another set of questions about healthcare-associated work, ritual
practices during the visit, and the health of her
fellow travelers. Her responses were unremarkable, although she said that on reflection several members of her group had mild abdominal
symptoms yesterday morning while on layover for
a connecting flight home. But none of them were
as bad as hers and seemed to self-resolve. They all
had shared the dodgy airport snack.
Feeling reassured, you complete the physical
examination, which is normal other than very
mild abdominal discomfort with deep palpation.
While washing your hands and reminding your patient to do so regularly, you ask your staff to provide her with oral rehydration solution followed
by water, and within  minutes in the waiting
room, her symptoms of orthostasis are gone and
her heart rate is  bpm. While she did not experience a bowel movement during the visit, given
the severity of her symptoms overnight as well as
REVIEW ARTICLE
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potential risk for fall and its consequences at her
age if she gets further behind in volume status,
you prescribe a brief course of antibacterial therapy, though you appreciate that other providers
might reasonably wait another day and follow her
symptoms. Thinking about her normal temperature (although in the upper part of the range) and
that not all people’s perceptions of what adherence means with antimalarial preventive medications are the same, you decide that you will call
her by telephone tomorrow to make sure that she
has not manifested a fever, her symptomatology
is improving, and that her group has not shown
more illness. She is not a food handler, daycare
provider, or healthcare worker, and so you are
not concerned about occupational restrictions
from a potentially communicable enteric disease.
Over the remainder of the day, you consider
how the visit and day would have been different
if the patient had been a healthcare missionary
closer to the DRC, a fever had been present, and
she had looked a bit sicker, or if she had presented from an area with novel influenza or had small
farm poultry exposure in Asia or camel or inpatient hospital contact in the Middle East and was
experiencing cough, or was a long-time healthcare missionary and presented with cough and
weight loss. You reflect that your concerns about
potential connection to a public health emergency did not appear in the clinic until PZ had registered at the desk, spent time in the waiting area
interacting with other patients, undergone triage, possibly used the bathroom or patient water
cooler, and come through to your office. Your clinic staff decides to have an end-of-day debrief on
the event and introduce signage so that patients
self-identify immediately when communicable
symptoms are present regardless of an itinerary
or a potential pathogen (eg, cough, rhinorrhea,
diarrhea, vomiting, bleeding), or an itinerary or
contact of concern; make handwashing and masks
readily available in the waiting room; and generate procedures for how to proceed when risk is
recognized. Additionally, you review the process
for alerting and seeking counsel from local public
health authorities, generate an explicit procedure
for contacting them incorporating their required
forms, when appropriate, and have an exploratory
call with those authorities to test that procedure.
You reflect on the original pretravel counseling
you provided to PZ and whether current circumstances would have made that counseling different, then implementing those changes systematically. You also think about the pervasive travel threats that more commonly impact travelers,
such as motor vehicle accidents, heat injury, insufficient preparation for chronic disease management or urgent and emergent care, and how
to ensure that they remain a key part of pretravel counseling and preparation even when focus
increases on emerging infectious diseases events.
Travel is an enriching and valuable
activity. It should be undertaken appreciating
Summary
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and managing the usual and unusual risks of
traveling, the pervasive threat and the emerging threats, and the particular needs of patients.
Ideally, when patients experience an illness while
traveling, they should contact their travel medicine physician. When they experience illness
following travel, they should exercise a predetermined plan for presenting for care. Anyone
might see such a patient before or after travel.
When they do, they should have a plan for conducting or referring the patient to get robust
pretravel advice and for receiving such patients
safely and effectively should they return with
an illness. Infection prevention and control as
well as public health requirements should be
considered. And, every case is an opportunity
to reflect and improve care practices.

ACKNOWLEDGMENTS The authors have no conflicts of interest. One
of the authors is an employee of the U.S. Government. As such, copyright is not available for this work. The views expressed in this article
are the authors’ and do not necessarily represent those of any agency of
the U.S. Government.
None declared.

OPEN ACCESS This is an Open Access article distributed under the terms
of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License (CC BY-NC-SA 4.0), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and
build upon the material, provided the original work is properly cited, distributed under the same license, and used for noncommercial purposes only. For
commercial use, please contact the journal office at pamw@mp.pl.
HOW TO CITE Wood SM, Brett-Major DM. Risk mitigation for travelers:
managing endemic and emerging threats. Pol Arch Intern Med. 2019; 129:
612-619. doi:10.20452/pamw.14946

REFERENCES
1 Vilkman K, Pakkanen SH, Lääveri T, et al. Travelers’ health problems
and behavior: prospective study with post-travel follow-up. BMC Infect Dis.
2016; 16: 328. "
2 Leder K, Torresi J, Libman MD, et al. GeoSentinel surveillance of illness
in returned travelers, 2007-2011. Ann Intern Med. 2013; 158: 456-468. "
3 Travelers’ Health: CDC Yellow Book. Centers for Disease Control and
Prevention website. https://wwwnc.cdc.gov/travel/page/yellowbook-home-2014. Updated July 18, 2019. Accessed August 22, 2019.
4 Angelo KM, Kozarsky PE, Ryan ET, et al. What proportion of international
travellers acquire a travel-related illness? A review of the literature. J Travel Med. 2017; 24. "
5 Harvey K, Esposito DH, Han P, et al. Surveillance for travel-related disease – GeoSentinel Surveillance System, United States, 1997-2011. MMWR
Surveill Summ. 2013; 62: 1-23.
6 LaRocque RC, Rao SR, Lee J, et al. Global TravEpiNet: a national consortium of clinics providing care to international travelers – analysis of demographic characteristics, travel destinations, and pretravel healthcare of
high-risk US international travelers, 2009-2011. Clin Infect Dis. 2012; 54:
455-462. "
7 Al-Abri SS, Abdel-Hady DM, Al-Abaidani IS. Knowledge, attitudes, and
practices regarding travel health among Muscat International Airport travelers in Oman: Identifying the gaps and addressing the challenges. J Epidemiol Glob Health. 2016; 6: 67-75. "
8 Freedman DO, Weld LH, Kozarsky PE, et al. Spectrum of disease and relation to place of exposure among ill returned travelers. N Engl J Med. 2006;
354: 119-130. "

16 Abdullah AS, Hamer DH. Travel-related health problems of Hong Kong
residents: Assessing the need for travel medicine services. Travel Med Infect Dis. 2006; 4: 324-331. "
17 Lohr J, Fredrick NB, Helm L, Cho J. Health guidelines for travel abroad.
Prim Care. 2018; 45: 541-554. "
18 Wilson ME. Travel and the emergence of infectious diseases. Emerg Infect Dis. 1995; 1: 39-46. "
19 Lewnard JA, Antillón M, Gonsalves G, et al. Strategies to prevent cholera introduction during international personnel deployments: a computational modeling analysis based on the 2010 Haiti outbreak. PLoS Med. 2016;
13: e1001947. "
20 Hendriksen RS, Price LB, Schupp JM, et al. Population genetics of Vibrio cholerae from Nepal in 2010: evidence on the origin of the Haitian outbreak. MBio. 2011; 2: e00157-11. "
21 Angell SY, Behrens RH. Risk assessment and disease prevention in
travelers visiting friends and relatives. Infect Dis Clin North Am. 2005; 19:
49-65. "

23 Boggild AK, Geduld J, Libman M, et al. Travel-acquired infections and
illnesses in Canadians: surveillance report from CanTravNet surveillance
data, 2009-2011. Open Med. 2014; 8: e20-e32.
24 Aldea M, García-Basteiro AL, Muñoz J, et al. Factors associated with
risk behavior in travelers to tropical and subtropical regions. Int Health.
2015; 7: 272-279. "
25 Schwartz E, Weld LH, Wilder-Smith A, et al. Seasonality, annual trends,
and characteristics of dengue among ill returned travelers, 1997-2006.
Emerg Infect Dis. 2008; 14: 1081-1088. "
26 Irving TJ, Blyuss KB, Colijn C, Trotter CL. Modelling meningococcal meningitis in the African meningitis belt. Epidemiol Infect. 2012; 140:
897-905. "
27 Koul PA, Mir H, Saha S, et al. Respiratory viruses in returning Hajj
& Umrah pilgrims with acute respiratory illness in 2014-2015. Indian J Med
Res. 2018; 148: 329-333. "
28 Muraduzzaman AK, Khan MH, Parveen R, et al. Event based surveillance of Middle East Respiratory Syndrome Coronavirus (MERS- CoV) in
Bangladesh among pilgrims and travelers from the Middle East: an update
for the period 2013-2016. PLoS One. 2018; 13: e0189914. "
29 Kim KH, Tandi TE, Choi JW, et al. Middle East respiratory syndrome
coronavirus (MERS -CoV) outbreak in South Korea, 2015: epidemiology,
characteristics and public health implications. J Hosp Infect. 2017; 95:
207-213. "
30 Media centre. Middle East respiratory syndrome coronavirus (MERS-CoV) in the Republic of Korea Situation assessment. World Health Organization website. https://www.who.int/mediacentre/news/situation-assessments/2-june-2015-south-korea/en/. Published June 2, 2015. Accessed August 25, 2019.
31 Chevalier MS, Chung W, Smith J, et al. Ebola virus disease cluster in
the United States-Dallas County, Texas, 2014. MMWR Morb Mortal Wkly
Rep. 2014; 63: 1087-1088.
32 Emergencies preparedness, response. Disease Outbreak News. World
Health Organization website. https://www.who.int/csr/don/en/. Accessed
August 25, 2019.
33 Alon D, Shitrit P, Chowers M. Risk behaviors and spectrum of diseases
among elderly travelers: a comparison of younger and older adults. J Travel
Med. 2010; 17: 250-255. "
34 Wieten RW, Leenstra T, Goorhuis A, et al. Health risks of travelers
with medical conditions—a retrospective analysis. J Travel Med. 2012; 19:
104-110. "
35 Schwartz BS, Rosen J, Han PV, et al. Immunocompromised travelers:
demographic characteristics, travel destinations, and pretravel health care
from the U.S. Global TravEpiNet Consortium. Am J Trop Med Hyg. 2015;
93: 1110-1116. "

9 Uslan DZ, Patel R, Virk A. International travel and exposure risks in solid-organ transplant recipients. Transplantation. 2008; 86: 407-412. "

36 Hall V, Johnson D, Torresi J. Travel and biologic therapy: travel-related
infection risk, vaccine response and recommendations. J Travel Med. 2018;
25. "

10 Kemper CA, Linett A, Kane C, Deresinski SC. Frequency of travel of
adults infected with HIV. J Travel Med. 1995; 2: 85-88. "

37 Aronson NE, Sanders JW, Moran KA. In harm’s way: infections in deployed American military forces. Clin Infect Dis. 2006; 43: 1045-1051. "

11 Salit IE, Sano M, Boggild AK, Kain KC. Travel patterns and risk behaviour of HIV-positive people travelling internationally. CMAJ. 2005; 172:
884-888. "

38 Gleeson M, Bishop N, Oliveira M, et al. Respiratory infection risk in athletes: association with antigen-stimulated IL-10 production and salivary IgA
secretion. Scand J Med Sci Sports. 2012; 22: 410-417. "

12 Hochberg NS, Barnett ED, Chen LH, et al. International travel by persons with medical comorbidities: understanding risks and providing advice.
Mayo Clin Proc. 2013; 88: 1231-1240. "

39 Thomson CA, Gibbs RA, Giele C, et al. Health seeking behaviours
and knowledge of infectious disease risks in Western Australian travellers to Southeast Asian destinations: an airport survey. Trop Med Infect Dis.
2016; 1. "

13 Adam DC, Bui CM, Heywood AE, et al. Adherence to anti-vectorial prevention measures among travellers with chikungunya and malaria returning
to Australia: comparative epidemiology. BMC Res Notes. 2018; 11: 590. "

618

15 Anula-Morales A, Martin-Giner B, Hernández-Cabrera M, et al. Non-febrile syndromes in the traveler returning from tropical regions admitted
in a monographic unit [in Spanish]. Rev Esp Quimioter. 2017; 30: 96-102.

22 Hagmann SH, Han PV, Stauffer WM, et al. Travel-associated disease
among US residents visiting US GeoSentinel clinics after return from international travel. Fam Pract. 2014; 31: 678-687. "

ARTICLE INFORMATION

CONFLICT OF INTEREST

14 Angelo KM, Libman M, Caumes E, et al. Malaria after international travel: a GeoSentinel analysis, 2003-2016. Malar J. 2017; 16: 293. "

POLISH ARCHIVES OF INTERNAL MEDICINE

2019; 129 (9)

40 Marano C, Moodley M, Melander E, et al. Perceptions of tick-borne encephalitis risk: a survey of travelers and travel clinics from

Canada, Germany, Sweden and the UK. J Travel Med. 2019; 26 (Suppl 1):
S10-S16. "
41 Heywood AE, Nothdurft H, Tessier D, et al. Pre-travel advice, attitudes
and hepatitis A and B vaccination rates among travelers from seven countries. J Travel Med. 2016; 24. "
42 Chen LH, Leder K, Barbre KA, et al. Business travel-associated illness:
a GeoSentinel analysis. J Travel Med. 2018; 25. "
43 Landry P, Iorillo D, Darioli R, et al. Do travelers really take their mefloquine malaria chemoprophylaxis? Estimation of adherence by an electronic
pillbox. J Travel Med. 2006; 13: 8-14. "
44 From the Centers for Disease Control and Prevention. Outbreak of acute
febrile illness among participants in EcoChallenge Sabah 2000 – Malaysia,
2000. JAMA. 2000; 284: 1646.
45 Fraser A, Paul M, Goldberg E, et al. Typhoid fever vaccines: systematic review and meta-analysis of randomized controlled trials. Vaccine. 2007;
25: 7848-1857. "
46 Bricks LF, Sato HK, Oselka GW. Varicella vaccines and measles,
mumps, rubella, and varicella vaccine. J Pediatr (Rio J). 2006; 82 (3 Suppl): S101-S108. "
47 Brett-Major DM, Lipnick RJ. Antibiotic prophylaxis for leptospirosis.
Cochrane Database Syst Rev. 2009; CD007342. "
48 Avni C, Stienlauf S, Meltzer E, et al. Region-specific, life-threatening
diseases among international travelers from Israel, 2004-2015. Emerg Infect
Dis. 2018; 24: 790-793. "
49 Ryan ET, Wilson ME, Kain KC. Illness after international travel. N Engl J
Med. 2002; 347: 505-516. "
50 Speil C, Mushtaq A, Adamski A, Khardori N. Fever of unknown origin
in the returning traveler. Infect Dis Clin North Am. 2007; 21: 1091-113, x. "
51 Miller JM, Binnicker MJ, Campbell S, et al. A Guide to Utilization of
the Microbiology Laboratory for Diagnosis of Infectious Diseases: 2018 Update by the Infectious Diseases Society of America and the American Society for Microbiology. Clin Infect Dis. 2018; 67: 813-816. "
52 Riddle MS. Current management of acute diarrheal infections in adults.
Pol Arch Intern Med. 2018; 128: 685-692. "
53 Brett-Major DM. Thinking about Ebola. J R Coll Physicians Edinb. 2015;
45: 15-17. "
54 Travelers’ health. Centers for Disease Control and Prevention website.
https://www.cdc.gov/travel/. Accessed August 25, 2019.

REVIEW ARTICLE

Risk mitigation for travelers

619

